Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis [2]

European Journal of Haematology

Volumn 74, Issue 3, 2005, Pages 273-274

  Leonidas, Benetatos ^a   Aristeidis, Chaidos ^a   Vasiliki, Alymara ^a   Amalia, Vassou ^a   Konstantinos, Bourantas L ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Dept of Int Med and Hematology ^*  (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CORTICOSTEROID; ERYTHROPOIETIN; HYDROXYUREA; METHYLPREDNISOLONE; THALIDOMIDE;

AGED; ANEMIA; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DROWSINESS; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; IDIOPATHIC DISEASE; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MYELOID METAPLASIA; NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SEDATION; SIDE EFFECT; SINUS BRADYCARDIA; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT; TREMOR;

ADRENAL CORTEX HORMONES; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; HUMANS; INFANT; MALE; MYELOFIBROSIS; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 14044277514     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00386.x     Document Type: Letter

References (10)

1. TEFFERI A. The forgotten myeloproliferative disorder: myeloid metaplasia. Oncologist 2003;8:225-231.
2. FRANKS ME, MACPHERSON GR, FIGG WD. Thalidomide. Lancet 2004;363:1802-1811.
3. TEFFERI A, SILVERSTEIN MN. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia (Correspondence). Br J Haematol 1994; 86:893-896.
4. BAROSI G, GROSSI A, COMOTTI B, MUSTO P, GAMBA G, MARCHETTI M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001;114:78-83.
5. VISANI G, MELE A, MALAGOLA M, ISIDORI A, FINELLI C, PICCALUGA PP. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents (Correspondence). Leukemia 2003;17:1669-1670.
6. PANTELI K, ZAGORIANAKOU N, BAI M, KATSARAKI A, AGNANTIS NJ, BOURANTAS K. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. Eur J Hematol 2004;72:410-415.
7. STRUPP C, GERMING U, SCHERER A, KUNDGEN A, MODDER U, GATTERMANN N, HAAS R. Thalidomide for the treatment of idiopatic myelofibrosis. Eur J Haematol 2004; 72:52-57.
8. MARCHETTI M, BAROSI G, BALESTRI F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrisis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004;22:424-431.
9. CHAIDOS A, BENETATOS L, ALYMARA V, VASSOU A, TSIARA S, HATZIMICHAEL E, BOURANTAS KL. Low-dose thalidomide and corticosteroids for the treatment of chronic idiopathic myelofibrosis (Abstract). The Hematol J 2004;5(supp 2): S313.
10. MESA RA, STEENSMA DP, PARDANANI A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541.